4.3 Article

EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer

Journal

NEOPLASIA
Volume 20, Issue 4, Pages 351-363

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neo.2018.01.011

Keywords

-

Categories

Funding

  1. National Institutes of Health [R01 CA186780, P50 CA180995, R50 CA211242, T32 DK007774]
  2. Tippins Foundation
  3. Mellam Family Foundation
  4. AUA Foundation
  5. [P30 CA047904]

Ask authors/readers for more resources

The tumor suppressor genes EAF2 and p53 are frequently dysregulated in prostate cancers. Recently, we reported that concurrent p53 nuclear staining and EAF2 downregulation were associated with high Gleason score. Combined loss of EAF2 and p53 in a murine model induced prostate tumors, and concurrent knockdown of EAF2 and p53 in prostate cancer cells enhanced proliferation and migration, further suggesting that EAF2 and p53 could functionally interact in the suppression of prostate tumorigenesis. Here, RNA-seq analyses identified differentially regulated genes in response to concurrent knockdown of p53 and EAF2. Several of these genes were associated with the STAT3 signaling pathway, and this was verified by significantly increased p-STAT3 immunostaining in the Eaf2(-/-) p53(-/-) mouse prostate. STAT3 knockdown abrogated the stimulation of C4-2 cell proliferation by concurrent knockdown of EAF2andp53. Furthermore, immunostaining of p-STAT3 was increased in human prostate cancer specimens with EAF2 downregulation and/or p53 nuclear staining. Our findings suggest that simultaneous inactivation of EAF2 and p53 can act to activate STAT3 and drive prostate tumorigenesis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available